Last reviewed · How we verify

KX2-391 Ointment 1% — Competitive Intelligence Brief

KX2-391 Ointment 1% (KX2-391 Ointment 1%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Src kinase inhibitor. Area: Dermatology.

phase 3 Src kinase inhibitor Src kinase Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

KX2-391 Ointment 1% (KX2-391 Ointment 1%) — Almirall, S.A.. KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KX2-391 Ointment 1% TARGET KX2-391 Ointment 1% Almirall, S.A. phase 3 Src kinase inhibitor Src kinase
Cryotherapy + Tirbanibulin Cryotherapy + Tirbanibulin University Hospital, Lille phase 3 Combination therapy: cryotherapy + Src kinase inhibitor Src kinase (tirbanibulin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Src kinase inhibitor class)

  1. Almirall, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KX2-391 Ointment 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/kx2-391-ointment-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: